Molecular Interaction Analyzer

As a label free biomolecule interaction analyzer, AiSPR-96Molecular Interaction AnalyzerThere is no longer a limit on the molecular weight of organic compounds. You can analyze sensitive or rare samples, accurately obtain data on extremely fast binding or very slow dissociation, and reliably reveal small differences in kinetics.

AiSPR-96Molecular Interaction AnalyzerBased on SPR technology, it is a 96 well plate biomolecule interaction analyzer that can achieve real-time analysis without labeling, providing you with high-quality kinetic, affinity, antibody screening, and concentration determination information. AiSPR-96 can accurately distinguish concentration differences at the picomolar level, allowing you to directly measure intermolecular interactions in the natural state of the sample without the need for some inferior alternative methods. AiSPR-96 provides valuable information on intermolecular interactions between biomolecules for various application fields, from basic scientific research, small molecule and biopharmaceutical development, to vaccine development and quality control.

Detailed analysis of intermolecular interactions is not simply described as the strength of affinity. By parsing affinity into real-time kinetic data, we can gain a deeper understanding of biological phenomena and make the connection between intermolecular interactions and their functions clearer.

The extended kinetic space provided by AiSPR-96 brings you tangible benefits, as you can obtain high-quality information related to interactions between biomolecules. Even for interactions with very complex dynamics, such as extremely fast binding processes and extremely slow dissociation processes, you can confidently measure them. You can accurately determine the true dissociation rate of antibody complexes with strong affinity, which is crucial for optimizing drug efficacy. You may also be able to capture subtle behavioral differences between rapidly binding molecules, which will help you screen for better drugs, especially when the physiological activity concentration is low after drug use.